Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ELVN
ELVN | US
44.44
USD-1.45
-3.16%
ELVN | US
About ELVN
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
22/04/2026
Close
44.44
Open
46.44
High
46.93
Low
44.14
Enliven Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001 which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002 a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder Colorado.
View LessELVN | US
Risk
85.3
Sharpe
2.01
Luna's Score
55/100
Recommendation
Hold
Luna says (ELVN | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Short percentage (> 15%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
57.1%1 month
85.3%3 months
67.5%6 months
99.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.49
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-6.28
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-95.95M
MarketCap
2.10B
MarketCap(USD)
2.10B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-28.37
Short ratio
26.76
Short perc.
31.97
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
6.15
Range1M
19.57
Range3M
23.64
Volumes: Market Activity
Rel. volume
0.47
Price X volume
33.07M
